Neoadjuvant chemotherapy is increasingly used to downstage tumors and optimize adjuvant treatment strategies in patients with stage II or III breast cancer, particularly those with HER2-positive breast cancer and TNBC [9,10]. Here, ERBB2 is linked to breast carcinoma.